Forbion raises €2.3bn, now Europe’s top biotech investor
Naarden-based venture capital firm Forbion, which specialises in life sciences companies, has raised €2.3 billion for 2 new biotech funds,...
Dutch venture capital firm Forbion has raised €2.3 billion for two new biotech funds, marking its largest fundraising in the last five years and positioning it as Europe's biggest specialist life sciences investor, according to data from Preqin. The firm's assets will now total €7.5 billion, with the funds earmarked for around 30 companies, ranging from early-stage ventures to those testing drugs on patients.
Some of the financing will extend to companies in North America as well as Europe. Dutch pension money managers MN and PGGM, alongside US drugmaker Eli Lilly, are among the investors. The presence of life sciences and biotechnology among the four sectors in which the Dutch cabinet aims to recruit highly skilled foreign workers underscores the importance of these industries in the national talent strategy.
Written by urgent.news from DutchNews's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
